<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00038610</url>
  </required_header>
  <id_info>
    <org_study_id>ID01-006</org_study_id>
    <secondary_id>NCI-2012-01487</secondary_id>
    <nct_id>NCT00038610</nct_id>
  </id_info>
  <brief_title>Study of Hyper-CVAD Plus Imatinib Mesylate for Philadelphia-Positive Acute Lymphocytic Leukemia</brief_title>
  <official_title>Phase II Study of Hyper-CVAD Plus Imatinib Mesylate (Gleevec, STI571) for Philadelphia-Positive Acute Lymphocytic Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this clinical research study is to learn if intensive chemotherapy, combined with
      imatinib mesylate (Gleevec, STI571) given for 8 courses over 6 months, followed by
      maintenance imatinib mesylate plus chemotherapy for 2 years, followed by imatinib mesylate
      indefinitely can improve Philadelphia-positive acute lymphoblastic leukemia. The safety of
      this treatment will also be studied.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Before treatment starts, patients will have a complete exam, including medical history and
      documentation of disease, blood, and marrow tests. A chest x-ray will be taken. CT scans may
      be taken if needed. A bone marrow sample will be taken through a large needle. An EKG and
      MUGA (heart function tests) will be performed.

      During treatment, patients will give blood samples (about 1 tablespoon each) at least twice a
      week. A bone marrow sample will be repeated 2 and 3 weeks from the beginning of treatment to
      check on response. After two courses of chemotherapy, the tests done before treatment will be
      repeated to check for response.

      All patients will receive 2 kinds of chemotherapy courses for a total of 8 courses.
      Chemotherapy courses will be given through a large vein by a central venous catheter (a
      plastic tube usually placed under the collarbone). Imatinib mesylate will be given as a pill
      with the chemotherapy.

      Course 1 will start with cyclophosphamide given by vein over 2-3 hours every 12 hours for 6
      doses over 3 days (Days 1,2,3). Mesna will be given by vein continuously for 4 days with the
      cyclophosphamide to protect the bladder. Doxorubicin will be given by vein over 24 hours on
      Day 4. Vincristine will be given by short infusion on Days 4 and 11. Dexamethasone (a
      steroid) will be given by mouth or by vein on Days 1-4 and 11-14. The imatinib mesylate will
      be given by mouth with breakfast and a large glass of water daily on Days 1-14. Medicines
      will be given to prevent nausea and to protect the kidneys from increased amounts of uric
      acid, which may be released when leukemia cells die.

      G-CSF (growth stimulating colony factor) will be given after completion of the chemotherapy.
      It is given to allow for rapid recovery of the normal marrow. G-CSF will be injected under
      the skin until the counts recover. Treatment to the brain will be given inside the spinal
      fluid with methotrexate around Day 2 and cytarabine about day 7. This is done to prevent the
      leukemia from developing there.

      For patients aged 60 years or older, this Course 1 will be given in a protective isolation
      room to decrease the risk of infection(s).

      During Course 2, patients will be given methotrexate by infusion over 24 hours on the first
      day and cytarabine at a high dose over 2 hours every 12 hours for 4 doses (Days 2 and 3).
      Citrovorum factor (leucovorin), an antidote for side effects of methotrexate, will be given
      by vein or by mouth for 2-3 days (Day 2 and on). Solumedrol (a steroid) will be given by vein
      every 12 hours for 6 doses. Imatinib mesylate will be given by mouth with breakfast and a
      large glass of water on Days 1-14 or daily, depending on tolerance with Course 1. G-CSF will
      be given as in Course 1. The treatment to the brain inside the spinal fluid will be given as
      in Course 1 around Days 2 and 7.

      The chemotherapy will alternate between hyper-CVAD plus imatinib mesylate (Courses 1, 3, 5,
      and 7) and methotrexate/cytarabine plus imatinib mesylate (Courses 2, 4, 6, and 8) to
      complete a total of 8 courses. G-CSF will be given as in Course 1. Anti-nausea medicine will
      be given with each course of chemotherapy. The urine will be alkalized to protect the
      kidneys. Antibiotics will be given by mouth to prevent infection.

      After the 8 courses, monthly maintenance chemotherapy plus imatinib mesylate will be given.
      This includes daily imatinib mesylate, monthly vincristine by vein, and prednisone by mouth
      for 5 days every month. Maintenance chemotherapy will be given for a total of 24 months, and
      will be interrupted by 2 periods of intensive chemotherapy courses with hyper-CVAD and
      imatinib mesylate at 6 and 13 months from the start of maintenance. Imatinib mesylate will be
      continued daily as tolerated indefinitely.

      After two courses of the intensive chemotherapy, the response to the treatment will be
      evaluated. If the leukemia is responding, the therapy will be continued. Patients will be
      taken off study if the leukemia starts to get worse.

      During and after completion of treatment, patients will have a complete exam, including blood
      tests. If needed, a chest X-ray or CT scan will be done. A bone marrow sample will be taken
      through a large needle. Patients will then return every 2 to 3 months for a checkup,
      including blood and bone marrow. X-rays and heart studies (MUGA or ECG) may be repeated if
      needed.

      An Ommaya reservoir may also be placed surgically as a route to treat leukemia in the brain
      or to prevent leukemia in patients who have difficulty with the spinal treatments. An Ommaya
      reservoir is an access port inserted under the skin of the scalp that enters into the spinal
      fluid cavity of the brain.

      Treatment will be given on an inpatient basis (3 to 5 days) for the 8 intensive courses of
      chemotherapy, or as indicated by the clinical condition. The maintenance treatments will be
      given as an outpatient, except for the courses of hyper-CVAD and imatinib mesylate.

      This is an investigational study. The FDA has approved imatinib mesylate for use in chronic
      myelogenous leukemia and other clinical research studies. About 55 patients will take part in
      this study. All will be from MD Anderson.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2001</start_date>
  <completion_date type="Actual">July 2014</completion_date>
  <primary_completion_date type="Actual">July 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response To Induction Therapy With Hyper-CVAD Plus Imatinib Mesylate</measure>
    <time_frame>Baseline to 6 months</time_frame>
    <description>Complete Remission (CR): Defined as the presence of 5% or less blasts in the bone marrow, with a granulocyte count of 1.0 × 109/L or higher and a platelet count of 100 × 109/L and no extramedullary disease.
Partial Response (PR): As above for CR except for the presence of 6-25% marrow blasts.
Molecular CR: Same as for CR with RT-PCR negativity for bcr-abl.
Induction Death: Defined as death occurring after start of therapy without meeting the definition of CR or resistant disease.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Disease-Free Survival Rate at 2-year and 5-year.</measure>
    <time_frame>Baseline to 2-year and 5-year</time_frame>
    <description>Disease-Free Survival (DFS) was calculated from the time of complete remission until relapse or death due to any cause.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival Rate at 2-year and 5-year.</measure>
    <time_frame>Baseline to 2-year and 5-year</time_frame>
    <description>Overall survival (OS) was calculated from the date of initiation of therapy until death.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">54</enrollment>
  <condition>Leukemia</condition>
  <arm_group>
    <arm_group_label>Hyper-CVAD + Imatinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Imatinib 600 mg orally days 1-14, course 1, &amp; 600 mg daily days 1-14 (daily if tolerated course 1), even courses. Cyclophosphamide 300 mg/m^2 intravenous (IV) for 6 doses days 1-3, odd courses. Doxorubicin 50 mg/m^2 IV day 4; Vincristine 2 mg IV days 4 &amp; 11; &amp; Dexamethasone 40 mg IV or orally daily days 1-4 &amp; 11-14 odd courses 1, 3, 5, 7. Methotrexate 12 mg intrathecally (6 mg if via Ommaya reservoir) day 2, odd courses and 200 mg/m^2 IV over 2 hours followed by 800 mg/m^2 over 22 hours day 1 of even courses. Cytarabine 100 mg intrathecally day 7 for odd courses and 3 gm/m^2 IV every 12 hours for 4 doses days 2-3 for even courses. Mesna 600 mg/m^2 IV daily, odd courses. G-CSF 10 mcg/kg/day after completion of chemotherapy until neutrophil recovery to 1 x 109/L or higher for all courses.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Imatinib Mesylate</intervention_name>
    <description>600 mg by mouth on days 1 - 14 for course 1, and 600 mg by mouth daily days 1-14 (or daily if tolerated with course 1) for courses 2, 4, 6, 8.</description>
    <arm_group_label>Hyper-CVAD + Imatinib</arm_group_label>
    <other_name>Gleevec</other_name>
    <other_name>Glivec</other_name>
    <other_name>Imatinib</other_name>
    <other_name>STI571</other_name>
    <other_name>STI-571</other_name>
    <other_name>CGP-57148B</other_name>
    <other_name>NSC-716051</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>300 mg/m^2 by vein every 12 hours for 6 doses days 1, 2, 3 (total dose 1800 mg/m^2) for courses 1, 3, 5, 7.</description>
    <arm_group_label>Hyper-CVAD + Imatinib</arm_group_label>
    <other_name>Cytoxan®,</other_name>
    <other_name>Neosar®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxorubicin</intervention_name>
    <description>50 mg/m^2 by vein on day 4 after last dose of CTX for courses 1, 3, 5, 7.</description>
    <arm_group_label>Hyper-CVAD + Imatinib</arm_group_label>
    <other_name>Adriamycin ®</other_name>
    <other_name>Rubex ®</other_name>
    <other_name>Adriamycin PFS</other_name>
    <other_name>Adriamycin RDF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vincristine</intervention_name>
    <description>2 mg by vein on day 4 and day 11 for courses 1, 3, 5, 7.</description>
    <arm_group_label>Hyper-CVAD + Imatinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>40 mg by vein or by mouth daily on days 1 - 4 and days 11 - 14 for courses 1, 3, 5, 7.</description>
    <arm_group_label>Hyper-CVAD + Imatinib</arm_group_label>
    <other_name>Decadron</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <description>12 mg intrathecally (6 mg if via Ommaya reservoir) day 2 for courses 1, 3, 5, 7.
200 mg/m^2 by vein over 2 hours followed by 800 mg/m^2 over 22 hours on day 1 of courses 2, 4, 6, 8.</description>
    <arm_group_label>Hyper-CVAD + Imatinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cytarabine</intervention_name>
    <description>100 mg intrathecally day 7 for courses 1, 3, 5, 7.
3 gm/m2 by vein over 2 hrs every 12 hrs for 4 doses on days 2 and 3 for courses 2, 4, 6, 8.</description>
    <arm_group_label>Hyper-CVAD + Imatinib</arm_group_label>
    <other_name>Ara-C</other_name>
    <other_name>Cytosar</other_name>
    <other_name>DepoCyt</other_name>
    <other_name>Cytosine Arabinosine Hydrochloride</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mesna</intervention_name>
    <description>600 mg/m^2 by vein daily for 24 hours for courses 1, 3, 5, 7.</description>
    <arm_group_label>Hyper-CVAD + Imatinib</arm_group_label>
    <other_name>Mesnex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>G-CSF</intervention_name>
    <description>10 mcg/kg/day after completion of chemotherapy until neutrophil recovery to 1 x 109/L or higher for all courses.</description>
    <arm_group_label>Hyper-CVAD + Imatinib</arm_group_label>
    <other_name>Filgrastim</other_name>
    <other_name>Neupogen</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Diagnosis of previously untreated Ph-positive ALL or previously treated in CR after
             1-2 courses of therapy or failure after one course of induction chemotherapy without
             imatinib mesylate.

          2. Age &gt; or = 15 years. Those &lt; 15 years of age will be treated under compassionate IND.

          3. Zubrod performance status &lt; or = 2 (ECOG Scale, Appendix A).

          4. Adequate liver function (bilirubin &lt; or = to 3.0 mg/dl, unless considered due to
             tumor), and renal function (creatinine &lt; or = to 3.0 mg/dl, unless considered due to
             tumor).

          5. Adequate cardiac function as assessed clinically by physical examination.

          6. Signed informed consent.

        Exclusion Criteria:

          1. Active serious infection not controlled by oral or intravenous antibiotics.

          2. Treatment with investigational antileukemic agent or chemotherapy agents in the last 7
             days before study entry, unless full recovery from side-effects has occurred or
             patient has rapidly progressive disease judged life-threatening.

          3. Active secondary malignancy other than skin cancer (e.g. basal cell carcinoma or
             squamous cell carcinoma) than in investigator's opinion will shorten survival to less
             than 1 year.

          4. History of Grade III/IV cardiac problems as defined by the New York Heart Association
             Criteria.

          5. Prior history of treatment with imatinib mesylate.

          6. Pregnancy or lactating in women of childbearing potential.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Naval Daver, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UT MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>University of Texas MD Anderson Cancer Center Website</description>
  </link>
  <verification_date>August 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 3, 2002</study_first_submitted>
  <study_first_submitted_qc>June 3, 2002</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 4, 2002</study_first_posted>
  <results_first_submitted>August 19, 2015</results_first_submitted>
  <results_first_submitted_qc>August 19, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 18, 2015</results_first_posted>
  <last_update_submitted>August 19, 2015</last_update_submitted>
  <last_update_submitted_qc>August 19, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 18, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Leukemia</keyword>
  <keyword>Lymphoblastic</keyword>
  <keyword>Acute</keyword>
  <keyword>Philadelphia-Positive</keyword>
  <keyword>Imatinib Mesylate</keyword>
  <keyword>Gleevec</keyword>
  <keyword>Glivec</keyword>
  <keyword>Imatinib</keyword>
  <keyword>STI571</keyword>
  <keyword>STI-571</keyword>
  <keyword>CGP-57148B</keyword>
  <keyword>NSC-716051</keyword>
  <keyword>Cyclophosphamide</keyword>
  <keyword>Cytoxan®,</keyword>
  <keyword>Neosar®</keyword>
  <keyword>Doxorubicin</keyword>
  <keyword>Adriamycin ®</keyword>
  <keyword>Rubex ®</keyword>
  <keyword>Adriamycin PFS</keyword>
  <keyword>Adriamycin RDF</keyword>
  <keyword>Vincristine</keyword>
  <keyword>Dexamethasone</keyword>
  <keyword>Decadron</keyword>
  <keyword>Methotrexate</keyword>
  <keyword>Cytarabine</keyword>
  <keyword>Ara-C</keyword>
  <keyword>Cytosar</keyword>
  <keyword>DepoCyt</keyword>
  <keyword>Cytosine Arabinosine Hydrochloride</keyword>
  <keyword>Mesna</keyword>
  <keyword>Mesnex</keyword>
  <keyword>G-CSF</keyword>
  <keyword>Filgrastim</keyword>
  <keyword>Neupogen</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>Imatinib Mesylate</mesh_term>
    <mesh_term>BB 1101</mesh_term>
    <mesh_term>Lenograstim</mesh_term>
    <mesh_term>Mesna</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment Period: March 28, 2001 to October 04, 2006. All recruitment done at The University of Texas (UT) MD Anderson Cancer Center.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Hyper-CVAD + Imatinib</title>
          <description>Imatinib 600 mg orally days 1-14, course 1, &amp; 600 mg daily days 1-14 (daily if tolerated course 1), even courses. Cyclophosphamide 300 mg/m^2 intravenous (IV) for 6 doses days 1-3, odd courses. Doxorubicin 50 mg/m^2 IV day 4; Vincristine 2 mg IV days 4 &amp; 11; &amp; Dexamethasone 40 mg IV or orally daily days 1-4 &amp; 11-14 odd courses 1, 3, 5, 7. Methotrexate 12 mg intrathecally (6 mg if via Ommaya reservoir) day 2, odd courses and 200 mg/m^2 IV over 2 hours followed by 800 mg/m^2 over 22 hours day 1 of even courses. Cytarabine 100 mg intrathecally day 7 for odd courses and 3 gm/m^2 IV every 12 hours for 4 doses days 2-3 for even courses. Mesna 600 mg/m^2 IV daily, odd courses. G-CSF 10 mcg/kg/day after completion of chemotherapy until neutrophil recovery to 1 x 109/L or higher for all courses.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="54"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="54"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Hyper-CVAD + Imatinib</title>
          <description>Imatinib 600 mg orally days 1-14, course 1, &amp; 600 mg daily days 1-14 (daily if tolerated course 1), even courses. Cyclophosphamide 300 mg/m^2 intravenous (IV) for 6 doses days 1-3, odd courses. Doxorubicin 50 mg/m^2 IV day 4; Vincristine 2 mg IV days 4 &amp; 11; &amp; Dexamethasone 40 mg IV or orally daily days 1-4 &amp; 11-14 odd courses 1, 3, 5, 7. Methotrexate 12 mg intrathecally (6 mg if via Ommaya reservoir) day 2, odd courses and 200 mg/m^2 IV over 2 hours followed by 800 mg/m^2 over 22 hours day 1 of even courses. Cytarabine 100 mg intrathecally day 7 for odd courses and 3 gm/m^2 IV every 12 hours for 4 doses days 2-3 for even courses. Mesna 600 mg/m^2 IV daily, odd courses. G-CSF 10 mcg/kg/day after completion of chemotherapy until neutrophil recovery to 1 x 109/L or higher for all courses.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="54"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51" lower_limit="17" upper_limit="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Response To Induction Therapy With Hyper-CVAD Plus Imatinib Mesylate</title>
        <description>Complete Remission (CR): Defined as the presence of 5% or less blasts in the bone marrow, with a granulocyte count of 1.0 × 109/L or higher and a platelet count of 100 × 109/L and no extramedullary disease.
Partial Response (PR): As above for CR except for the presence of 6-25% marrow blasts.
Molecular CR: Same as for CR with RT-PCR negativity for bcr-abl.
Induction Death: Defined as death occurring after start of therapy without meeting the definition of CR or resistant disease.</description>
        <time_frame>Baseline to 6 months</time_frame>
        <population>Of the 54 participants, 39 (72%) presented with de novo disease, 6 (11%) were refractory to standard induction therapy, and 9 (17%) entered the study in complete remission (CR) after one course of standard induction therapy.</population>
        <group_list>
          <group group_id="O1">
            <title>Hyper-CVAD + Imatinib</title>
            <description>Imatinib 600 mg orally days 1-14, course 1, &amp; 600 mg daily days 1-14 (daily if tolerated course 1), even courses. Cyclophosphamide 300 mg/m^2 intravenous (IV) for 6 doses days 1-3, odd courses. Doxorubicin 50 mg/m^2 IV day 4; Vincristine 2 mg IV days 4 &amp; 11; &amp; Dexamethasone 40 mg IV or orally daily days 1-4 &amp; 11-14 odd courses 1, 3, 5, 7. Methotrexate 12 mg intrathecally (6 mg if via Ommaya reservoir) day 2, odd courses and 200 mg/m^2 IV over 2 hours followed by 800 mg/m^2 over 22 hours day 1 of even courses. Cytarabine 100 mg intrathecally day 7 for odd courses and 3 gm/m^2 IV every 12 hours for 4 doses days 2-3 for even courses. Mesna 600 mg/m^2 IV daily, odd courses. G-CSF 10 mcg/kg/day after completion of chemotherapy until neutrophil recovery to 1 x 109/L or higher for all courses.</description>
          </group>
        </group_list>
        <measure>
          <title>Response To Induction Therapy With Hyper-CVAD Plus Imatinib Mesylate</title>
          <description>Complete Remission (CR): Defined as the presence of 5% or less blasts in the bone marrow, with a granulocyte count of 1.0 × 109/L or higher and a platelet count of 100 × 109/L and no extramedullary disease.
Partial Response (PR): As above for CR except for the presence of 6-25% marrow blasts.
Molecular CR: Same as for CR with RT-PCR negativity for bcr-abl.
Induction Death: Defined as death occurring after start of therapy without meeting the definition of CR or resistant disease.</description>
          <population>Of the 54 participants, 39 (72%) presented with de novo disease, 6 (11%) were refractory to standard induction therapy, and 9 (17%) entered the study in complete remission (CR) after one course of standard induction therapy.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Complete Remission</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Partial Remission</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Molecular Complete Remission</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Induction Death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival Rate at 2-year and 5-year.</title>
        <description>Overall survival (OS) was calculated from the date of initiation of therapy until death.</description>
        <time_frame>Baseline to 2-year and 5-year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Hyper-CVAD + Imatinib</title>
            <description>Imatinib 600 mg orally days 1-14, course 1, &amp; 600 mg daily days 1-14 (daily if tolerated course 1), even courses. Cyclophosphamide 300 mg/m^2 intravenous (IV) for 6 doses days 1-3, odd courses. Doxorubicin 50 mg/m^2 IV day 4; Vincristine 2 mg IV days 4 &amp; 11; &amp; Dexamethasone 40 mg IV or orally daily days 1-4 &amp; 11-14 odd courses 1, 3, 5, 7. Methotrexate 12 mg intrathecally (6 mg if via Ommaya reservoir) day 2, odd courses and 200 mg/m^2 IV over 2 hours followed by 800 mg/m^2 over 22 hours day 1 of even courses. Cytarabine 100 mg intrathecally day 7 for odd courses and 3 gm/m^2 IV every 12 hours for 4 doses days 2-3 for even courses. Mesna 600 mg/m^2 IV daily, odd courses. G-CSF 10 mcg/kg/day after completion of chemotherapy until neutrophil recovery to 1 x 109/L or higher for all courses.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival Rate at 2-year and 5-year.</title>
          <description>Overall survival (OS) was calculated from the date of initiation of therapy until death.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>2-year OS rate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5-year OS rate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Disease-Free Survival Rate at 2-year and 5-year.</title>
        <description>Disease-Free Survival (DFS) was calculated from the time of complete remission until relapse or death due to any cause.</description>
        <time_frame>Baseline to 2-year and 5-year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Hyper-CVAD + Imatinib</title>
            <description>Imatinib 600 mg orally days 1-14, course 1, &amp; 600 mg daily days 1-14 (daily if tolerated course 1), even courses. Cyclophosphamide 300 mg/m^2 intravenous (IV) for 6 doses days 1-3, odd courses. Doxorubicin 50 mg/m^2 IV day 4; Vincristine 2 mg IV days 4 &amp; 11; &amp; Dexamethasone 40 mg IV or orally daily days 1-4 &amp; 11-14 odd courses 1, 3, 5, 7. Methotrexate 12 mg intrathecally (6 mg if via Ommaya reservoir) day 2, odd courses and 200 mg/m^2 IV over 2 hours followed by 800 mg/m^2 over 22 hours day 1 of even courses. Cytarabine 100 mg intrathecally day 7 for odd courses and 3 gm/m^2 IV every 12 hours for 4 doses days 2-3 for even courses. Mesna 600 mg/m^2 IV daily, odd courses. G-CSF 10 mcg/kg/day after completion of chemotherapy until neutrophil recovery to 1 x 109/L or higher for all courses.</description>
          </group>
        </group_list>
        <measure>
          <title>Disease-Free Survival Rate at 2-year and 5-year.</title>
          <description>Disease-Free Survival (DFS) was calculated from the time of complete remission until relapse or death due to any cause.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>2-year DFS rate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5-year DFS rate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events and serious adverse events were collected from receiving of induction therapy to discontinuation of study drug. Collection period: April, 2001 to June 2013.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Hyper-CVAD + Imatinib</title>
          <description>Imatinib 600 mg orally days 1-14, course 1, &amp; 600 mg daily days 1-14 (daily if tolerated course 1), even courses. Cyclophosphamide 300 mg/m^2 intravenous (IV) for 6 doses days 1-3, odd courses. Doxorubicin 50 mg/m^2 IV day 4; Vincristine 2 mg IV days 4 &amp; 11; &amp; Dexamethasone 40 mg IV or orally daily days 1-4 &amp; 11-14 odd courses 1, 3, 5, 7. Methotrexate 12 mg intrathecally (6 mg if via Ommaya reservoir) day 2, odd courses and 200 mg/m^2 IV over 2 hours followed by 800 mg/m^2 over 22 hours day 1 of even courses. Cytarabine 100 mg intrathecally day 7 for odd courses and 3 gm/m^2 IV every 12 hours for 4 doses days 2-3 for even courses. Mesna 600 mg/m^2 IV daily, odd courses. G-CSF 10 mcg/kg/day after completion of chemotherapy until neutrophil recovery to 1 x 109/L or higher for all courses.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Pericardial and pleural effusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="35" subjects_affected="35" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="54" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>EDEMA</sub_title>
                <counts group_id="E1" events="8" subjects_affected="6" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>DYSRHYTHMIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>HYPOTENSION</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>TACHYCARDIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>CARDIAC</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>CONSTIPATION</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>DEHYDRATION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>DIARRHEA</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>GASTRITIS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>HEMORRHOIDAL BLEED</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>NAUSEA ALONE</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>VOMITING</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>STOMATITIS</sub_title>
                <counts group_id="E1" events="4" subjects_affected="1" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>FATIGUE</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>FEVER WITHOUT NEUTROPENIA</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>PLEURITIC PAIN</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>EPISTAXIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>BACK PAIN</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>FEVER NEUTROPENIC</sub_title>
                <counts group_id="E1" events="13" subjects_affected="7" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>INFECTION FEBRILE NEUTROPENIA</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>INFECTION NEUTROPENIC</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>INFECTION WITHOUT NEUTROPENIA</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>WOUND INFECTION</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>INFECTION</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>ALBUMIN, SERUM-LOW</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>BILIRUBIN INCREASE</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>GLUCOSE, SERUM-HIGH</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>HYPERGLYCEMIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>HYPOGLYCEMIA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>HYPOKALEMIA</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>HYPONATREMIA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>HYPOMAGNESEMIA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>TRANSAMINASE INCREASE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>HYPOCALCEMIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>CREATININE INCREASE</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>FIBRINOGEN DECREASE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>BONE PAIN</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>MOTOR</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>MYALGIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>FRACTURE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>DIZZINESS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>SENSORY</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>SYNCOPE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>SPEECH IMPAIRMENT</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>RENAL GENITOURINARY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>URINARY TRACT INFECTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>DYSPNEA</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>PLEURAL EFFUSION</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>HICCUPS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>SORE THROAT</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>PNEUMOTHORAX</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>PRURITUS/ITCHING</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>THROMBOSIS/EMBOLISM</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Naval Daver, MD/Leukemia</name_or_title>
      <organization>The University of Texas (UT) MD Anderson Cancer Center</organization>
      <email>CR_Study_Registration@mdanderson.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

